Loading…
Loading…
The ProShares Ultra SmallCap600 fund is designed to produce daily investment outcomes, before accounting for fees and expenses, that are two times (2x) the daily performance of the S&P SmallCap 600 index.
Is SAA's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Passive aggregate bond strategies have long been default options for advisors and investors looking to defray risk in equity-heavy portfolios while adding a reliable income sleeve. However, many of the ETFs and index funds tracking the Bloomberg U.S. Aggregate Bond Index and other related benchmarks come with drawbacks some market participants overlook.
ProShares Ultra SmallCap600 (NYSEARCA:SAA - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 1,964 shares, an increase of 21.9% from the January 15th total of 1,611 shares. Currently, 0.2% of the company's shares are sold short.
Two of the UK's mid-tier advertising outfits provided an unwelcome start to the week, with bothM&C Saatchi PLC (AIM:SAA) and S4 Capital PLC (LSE:SFOR, OTC:SCPPF) warning that trading has turned trickier as the year-end approaches. Neither update was scheduled, which tells its own story.
Shares in M&C Saatchi PLC (AIM:SAA) and S4 Capital PLC (LSE:SFOR, OTC:SCPPF) sank 6% and 7% after both groups warned that 2025 will fall short of expectations. The updates underline how fragile demand remains across the advertising and marketing landscape, where budgets are still being trimmed and visibility is patchy as clients head into the year-end planning season.
LONDON--(BUSINESS WIRE)--Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a cell therapy pioneer working to turn cells into powerful therapeutics, announced positive interim study results for omidubicel, a stem cell transplant therapy, in treating Severe Aplastic Anemia (SAA). The findings were shared by Dr. Ronit Simantov, Chief Medical and Scientific Officer of Gamida Cell, during a presentation at the 2025 Association for the Advancement of Blood & Biother.